Dynatrace, Inc. (DT) · Nov 3, 2026 · Earnings
Beat — Non-GAAP EPS $0.54 vs ~$0.49 consensus; revenue $579.9M vs ~$568.0M
Dynatrace earnings beat Q2 estimates and lifted FY27 revenue and ARR guidance, but Arize integration and higher share counts reduce profit targets.
Dynatrace is moving from core application observability toward full-lifecycle AI observability, using the completed Arize acquisition to cover AI development, evaluation, and production monitoring. The quarter itself beat the market’s bar. Non-GAAP EPS was $0.54 versus published consensus of about $0.49, while revenue reached $579.9 million versus roughly $568.0 million expected. The underlying business also remained healthy: ARR grew 16% and revenue grew 17% year over year. (Financial Highlights)
Management raised the growth outlook, largely because Arize is now contributing. Full-year ARR guidance increased by $34 million at the midpoint and revenue guidance by $22 million, with constant-currency ARR growth now expected at 17.5%-18.5%. The filing says the Arize acquisition is expected to add about 200 basis points to ARR growth. (Financial Outlook) 〔0〕
| Metric | Q2 2026 | Comparison |
|---|---|---|
| Non-GAAP diluted EPS (Financial Highlights) | $0.54 | $0.49 consensus |
| Revenue (Financial Highlights) | $579.9M | $568.0M consensus |
| FY27 ARR midpoint (Financial Outlook) | $2.403B | $2.369B prior guide |
| FY27 revenue midpoint (Financial Outlook) | $2.335B | $2.313B prior guide |
| FY27 non-GAAP operating margin (Financial Outlook) | 28.125% | 29.625% prior guide |
| FY27 non-GAAP diluted EPS midpoint (Financial Outlook) | $1.89 | $1.98 prior guide |
| Q3 non-GAAP diluted EPS midpoint (Financial Outlook) | $0.445 | $0.48 consensus |
The trade-off is meaningful: faster growth, weaker near-term earnings power. Dynatrace cut full-year non-GAAP operating-income guidance by $29 million, lowered EPS guidance by $0.09, and increased expected diluted shares by 11 million at the midpoint. The company explicitly attributes 175 basis points of margin dilution to Arize, while the filing also says the outlook excludes buybacks after September 30. (Financial Outlook)
The new buyback supports capital returns but does not change the operating story yet. The additional $1 billion authorization lifts total remaining capacity to about $1.3 billion, funded from cash and future cash flow; however, the program has no timetable and does not obligate Dynatrace to repurchase shares. (Share Repurchase Program)
Bottom line: This was a genuine quarterly beat and a clear acceleration in the top-line outlook, but the benefit is being bought with lower margins and earnings guidance. The business story improves on growth, while the near-term profit story becomes more complicated.
Investor Day and multi-year targets, February 16, 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!